Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Neurol Open

1 *eTable 1 Demographic results by cohort, diagnosis within cohort, and total patient population; values followed by "n=" denoted the number of*

2 *non-missing data values.*

3 *eTable 2 Clinical and laboratory results by cohort, diagnosis within cohort, and total patient population; values followed by "n=" denote the*

4 *number of non-missing data values.*

5 *etable 3 Clinician-derived outcomes at 6 months and 12 months post-onset. For each measurement, "n=" denotes the number of patients in the*

6 *sample with data recorded.*

7 *eTable 4 PROMIS Parent Proxy scores at 6 months and 12 months post-onset. For each measurement, "n=" denotes the number of patients in the*

8 *sample with data recorded.*

9 *eTable 5 PROMIS Pediatric scores at 6 months and 12 months post-onset. For each measurement, "n=" denotes the number of patients in the*

10 *sample with data recorded.*

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Neurol Open

11 *eTable 1. Demographic results by cohort, diagnosis within cohort, and total patient population; values followed by "n=" denoted the number of*

12 *non-missing data values.*

	In-Person Cohort			Virtual Cohort			Total
	TM	AFM	Total	TM	AFM	Total	
n	26	34	60	13	17	30	90
Female	12 (46%)	10 (29%)	22 (37%)	7 (54%)	7 (41%)	14 (47%)	36 (40%)
Age at Onset							
Median (range)	11.0 (0.3 – 17.9)	4.5 (0.9 – 13.5)	5.3 (0.3 – 17.9)	4.7 (0.3 – 12.6), n=12	8.6 (0.6 – 14.8), n=15	7.1 (0.3 – 14.8), n=27	5.5 (0.3 – 17.9), n=87
Race							
Caucasian	21 (81%)	23 (68%)	44 (73%)	13 (100%)	14 (82%)	27 (90%)	71 (79%)
African American	1 (4%)	4 (12%)	5 (8%)	0	0	0	5 (6%)
Asian	1 (4%)	3 (9%)	4 (7%)	0	1 (6%)	1 (3%)	5 (6%)
More Than One Race	1 (4%)	3 (9%)	4 (7%)	0	1 (6%)	1 (3%)	5 (6%)
Preferred Not to Answer	2 (8%)	1 (3%)	3 (5%)	0	1 (6%)	1 (3%)	4 (4%)
Ethnicity							
Hispanic or Latino	5 (19%)	7 (21%)	12 (20%)	2 (17%), n=12	1 (6%)	3 (10%), n=29	15 (17%), n=89
Preferred Not to Answer	0	2 (6%)	2 (3%)	0	0	0	2 (2%), n=89
Illness Within 3 Months of Onset	14 (61%), n=23	29 (85%)	43 (75%), n=57	9 (69%)	11 (73%), n=15	20 (71%), n=28	63 (74%), n=85

TM: Transverse Myelitis; AFM: Acute Flaccid Myelitis; std. dev.: standard deviation

13

14

2

15 *eTable 2. Clinical and laboratory results by cohort, diagnosis within cohort, and total patient population; values followed by "n=" denote the*

16 *number of non-missing data values.*

	In-Person Cohort			Virtual Cohort			Total
	TM	AFM	Total	TM	AFM	Total	Total
n	26	34	60	13	17	30	90
Symptoms at Onset							
Weakness							
Upper Extrem. Only	5 (19%)	13 (38%)	18 (30%)	1 (8%)	6 (38%), n=16	7 (24%), n=29	25 (28%), n=89
Lower Extrem. Only	14 (54%)	9 (26%)	23 (38%)	9 (69%)	8 (50%), n=16	17 (59%), n=29	40 (45%), n=89
Both Upper and Lower Extrem.	6 (23%)	10 (29%)	16 (27%)	3 (23%)	2 (13%), n=16	5 (17%), n=29	21 (24%), n=89
Numbness							
Upper Extrem. Only	0	2 (6%)	2 (3%)	0	1 (6%), n=16	1 (3%), n=29	3 (3%), n=89
Lower Extrem. Only	9 (35%)	6 (18%)	15 (25%)	2 (15%)	6 (35%), n=16	8 (27%), n=29	23 (26%), n=89
Both Upper and Lower Extrem.	1 (4%)	0	1 (2%)	1 (8%)	0, n=16	1 (3%), n=28	2 (2%), n=89
Laboratory Results							
CSF WBC (cells/mm^3)							
Median (range)	2 (0-709), n=20	13 (0-287), n=28	9 (0-709), n=48	12 (0-501), n=10	35 (1-89), n=15	17 (0-501), n=25	10 (0-709), n=73
CSF Protein (mg/dL)							
Median (range)	47 (23-148), n=20	40 (18-596), n=27	45 (18-596), n=47	48 (20-722), n=10	37.5 (28-69), n=14	42 (20-722), n=24	44 (18-722), n=71
Oligoclonal Bands Present	2 (11%), n=18	0, n=18	2 (6%), n=36	0, n=10	0, n=11	0, n=21	2 (4%), n=57
Enterovirus							
Positive	2 (8%)	14 (41%)	16 (27%)	1 (8%)	4 (24%), n=16	5 (17%), n=29	21 (24%), n=89
Not Tested	8 (31%)	7 (21%)	15 (25%)	6 (46%)	4 (24%), n=16	10 (33%), n=29	25 (28%), n=89

TM: Transverse Myelitis; AFM: Acute Flaccid Myelitis; std. dev.: standard deviation; CSF: Cerebrospinal Fluid; WBC: White Blood Cells

17
18
19
20

3

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Neurol Open

21   *eTable 3. Clinician-derived outcomes at 6 months and 12 months post-onset. For each measurement, "n=" denotes the number of patients in the sample with data recorded.*

| | TM | AFM | AFM Subtypes | |
			Grey Matter	Mixed Matter
6 Months Post-Onset				
WeeFIM				
Median Self-Care (range)	9 (6-24), n = 3	17.5 (6-42), n = 12	26 (14-42), n = 7	8 (6-42), n = 4
Median Sphincter Control (range)	4 (4-28), n = 3	21 (4-28), n = 12	28 (4-28), n = 7	4 (4-28), n = 4
Median Transfer (range)	3 (3-9), n = 3	10 (3-21), n = 12	19 (3-21), n = 7	3 (3-21), n = 4
Median Locomotion (range)	2 (2-5), n = 3	9 (2-14), n = 12	10 (3-14), n = 7	4 (2-14), n = 4
Median Communication (range)	8 (2-14), n = 3	10 (2-14), n = 12	10 (10-14), n = 7	5.5 (2-14), n = 4
Median Social Cognition (range)	11 (3-21), n = 3	13 (3-21), n = 12	15 (10-21), n = 7	7.5 (3-21), n = 4
Median Motor Subset (range)	18 (15-66), n = 3	52 (15-105), n = 12	83 (26-105), n = 7	19 (15-105), n = 4
Median Cognitive Subset (range)	19 (5-35), n = 3	23 (5-35), n = 12	25 (20-35), n = 7	13 (5-35), n = 4
Median Total (range)	37 (20-101), n = 3	73.5 (20-140), n = 12	108 (49-140), n = 7	32 (20-140), n = 4
Median Hauser Ambulation Index (range)	4 (0-9), n = 12	5 (0-9), n =20	0 (0-9), n = 10	9 (0-9), n = 9
Median 25-Foot Timed Walk (seconds) (range)	3.7 (3.0-19.7), n = 7	4.8 (4.1-9.9), n = 8	4.8 (4.1-9.9), n = 6	4.9 (4.8, 5.0), n = 2
Median 6-Minute Walk (feet) (range)	1890.3 (1195-1902), n = 4	1409.6 (0.0-1873.4), n = 10	1409.6 (1330-1873.4), n = 6	1440.5 (0-1676), n = 4
12 Months Post-Onset				
WeeFIM				
Median Self-Care (range)	19 (10-35), n = 8	20 (6-42), n = 18	25 (7-42), n = 10	14 (6-42), n = 7
Median Sphincter Control (range)	11 (4-28), n = 8	19.5 (4-28), n = 18	23 (4-28), n = 10	4 (4-28), n = 7
Median Transfer (range)	6.5 (3-21), n = 8	13.5 (3-21), n = 18	16.5 (3-21), n = 10	5 (3-17), n = 7
Median Locomotion (range)	6 (4-14), n = 8	11.5 (2-14), n = 18	12 (5-14), n = 10	9 (2-14), n = 7
Median Communication (range)	12.5 (3-14), n = 8	12 (6 -14), n = 18	11.5 (7-14), n = 10	12 (9-14), n = 7
Median Social Cognition (range)	18 (3-21), n = 8	17.5 (7-21), n = 18	17 (10-21), n = 10	18 (12-21), n = 7
Median Motor Subset (range)	45.5 (21-98), n = 8	53.5 (15-105), n = 18	71 (31-105), n = 10	37 (15-105), n = 7
Median Cognitive Subset (range)	30 (6-35), n = 8	28 (13-35), n = 18	28 (17-35), n = 10	30 (24-35), n = 7
Median Total (range)	78 (29-130), n = 8	78.5 (39-140), n = 18	98.5 (54-140), n = 10	67 (39-140), n = 7
Median Hauser Ambulation Index (range)	2 (0-9), n = 10	1.5 (0-9), n = 22	0 (0-8), n = 11	7 (0-9), n = 8
Median 25-Foot Timed Walk (seconds) (range)	4.5 (3.7-9.5), n = 5	4.9 (3.8-6.8), n = 9	4.9 (4.3-6.8), n = 5	5.4 (4.2-5.4), n = 3
Median 6-Minute Walk (feet) (range)	1641.5 (1148-2135), n = 2	1535.6 (500-1771), n = 9	1666.5 (1276-1771), n = 6	947 (500-1394), n = 2

TM: Transverse Myelitis; AFM: Acute Flaccid Myelitis

22

4

23 *eTable 4. PROMIS Parent Proxy scores at 6 months and 12 months post-onset. For each measurement, "n=" denotes the number of patients in the sample with data recorded.*

			AFM Subtypes	
	TM	AFM	Grey Matter	Mixed Matter
6 Months Post-Onset				
Median Anxiety (range)	33 (16-40), n = 15	32 (13-40), n = 17	32 (25-40), n = 8	37 (13-40), n = 8
Median Depression (range)	28 (10-30), n = 16	24 (16-30), n = 18	24 (19-30), n = 8	29 (16-30), n = 9
Median Tiredness (range)	34.5 (13-50), n = 14	40 (24-50), n = 17	40 (33-50), n = 7	42 (24-50), n = 9
Median Pain (range)	35 (10-40), n = 7	37 (24-40), n = 9	40 (24-40), n = 5	35.5 (28-140), n = 4
Median Peer (range)	12 (7-35), n = 16	9 (7-19), n = 16	7 (7-14), n = 8	11 (7-19), n = 7
Median Mobility (range)	30.5 (10-40), n = 14	33 (8-40), n = 14	34 (8-40), n = 7	24 (8 -38), n = 7
Median Upper Extremity (range)	38 (19-40), n = 14	33.5 (17-40), n = 14	26 (17-40), n = 7	36 (23-40), n = 7
12 Months Post-Onset				
Median Anxiety (range)	33 (16-40), n = 15	32.5 (13-40), n = 22	29.5 (13-38), n = 12	36 (22-40), n = 8
Median Depression (range)	29 (12-30), n = 13	27.5 (16-30), n = 22	27.5 (16-30), n = 12	29.5 (21-30), n = 8
Median Tiredness (range)	37 (12-50), n = 13	40 (22-50), n = 20	41 (24-50), n = 10	43 (22-50), n = 8
Median Pain (range)	40 (11-40), n = 9	40 (25-40), n = 15	40 (32-40), n = 9	40 (25-40), n = 5
Median Peer (range)	8.5 (7-21), n = 14	10.5 (7-19), n = 20	13 (7-15), n = 11	7 (7-19), n = 7
Median Mobility (range)	32 (8-40), n = 14	34 (10-40), n = 19	34 (10-40), n = 11	34 (13-40), n = 7
Median Upper Extremity (range)	38.5 (17-40), n = 14	34.5 (8-40), n = 16	32.5 (8-40), n = 8	37.5 (29-40), n = 6

TM: Transverse Myelitis; AFM: Acute Flaccid Myelitis

24

5

25
26
eTable 5. PROMIS Pediatric scores at 6 months and 12 months post-onset. For each measurement, "n=" denotes the number of patients in the sample with data recorded.

	TM	AFM	AFM Subtypes	
			Grey Matter	Mixed Matter
6 Months Post-Onset				
Median Anxiety (range)	11 (8-29), n = 15	14 (8-33), n = 13	10 (8-25), n = 5	14 (8-33), n = 7
Median Depression (range)	8 (8-29), n = 15	11.5 (8-22), n = 12	11 (8-22), n = 4	9 (8-22), n = 7
Median Tiredness (range)	14 (10-36), n = 13	14 (10-36), n = 12	12 (10-23), n = 5	20 (10-36), n = 7
Median Pain (range)	8 (8-34), n = 7	8 (8-12), n = 7	8 (8-8), n = 3	9 (8-12), n = 4
Median Peer (range)	31.5 (24-36), n = 12	31 (24-36), n = 11	31 (30-36), n = 5	35 (24-36), n = 5
Median Mobility (range)	36 (8-40), n = 12	25.5 (10-40), n = 12	39 (13-40), n = 5	24.5 (10-37), n = 6
Median Upper Extremity (range)	39 (26-40), n = 15	39 (16-40), n = 11	40 (37-40), n = 5	31.5 (16-40), n = 6
12 Months Post-Onset				
Median Anxiety (range)	12.5 (8-29), n = 12	14 (8-39), n = 12	16 (8-39), n = 5	12 (8-35), n = 5
Median Depression (range)	8 (8-27), n = 13	10 (8-26), n = 12	8 (8-24), n = 5	12 (8-26), n = 5
Median Tiredness (range)	13.5 (10-41), n = 12	11 (10-42), n = 11	10 (10-18), n = 5	27 (10-42), n = 4
Median Pain (range)	8 (8-28), n = 9	9 (8-39), n = 5	8 (8-8), n = 1	33 (9-39), n = 3
Median Peer (range)	36 (8-36), n = 13	34 (16-36), n = 11	28.5 (16-36), n = 4	34 (27-36), n = 5
Median Mobility (range)	33.5 (14-40), n = 10	37 (10-40), n = 9	38.5 (16-40), n = 4	25 (10-40), n = 4
Median Upper Extremity (range)	38 (26-40), n = 12	39 (8-40), n = 11	39.5 (37-40), n = 4	28 (8-40), n = 5

TM: Transverse Myelitis; AFM: Acute Flaccid Myelitis

27
28
29

30

6